Booster COVID Shot From Pfizer-BioNTech Significantly Cuts Infection Risk, Israel Study Shows - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

According to data published by the Health Ministry of Israel, the third dose of Pfizer Inc PFE - BioNTech SE's BNTX's COVID-19 vaccine has significantly improved protection from infection and serious illness in people aged 60 and older compared with those who received two shots.
Full details of the study were not released.
Related: Pfizer-BioNTech's COVID-19 Vaccine Becomes First To Receive Full FDA Approval
The findings were on par with separate statistics reported last week by Israel's Maccabi healthcare provider.
Ministry officials said that the protection against infection provided from 10 days after a third dose was four times higher than after two doses.
The booster also provided five to six times stronger protection against hospitalization or serious illness after 10 days in people aged 60 years and above.
Israel started administering third jabs to over 60-year-olds on July 30. On Thursday, it dropped the age of eligibility for a booster to 40 and included pregnant women, teachers, and health care workers below that age.
Third doses are given only to those who received their second shot at least five months ago.
Price Action: PFE shares closed up 2.50% at $49.93, and BNTX stock closed up 9.58% at $382.10 on Monday.
Photo by x3 from Pixabay